Picture: © Euroseeds

The European Court of Justice ruling from 2018 which put the latest breeding methods under the EU GMO legislation was a huge pushback for plant breeding innovation in the EU. With the proposal for a new regulation for certain new genomic techniques (NGTs) published on 5 July 2023, some faith in a rebirth of plant breeding innovation may just start to return.

© Nature Design - pixabay.com

Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.

Coffee cell cultures. © VTT

Scientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production.

Prof. Dr. Dr. Ulrike Köhl, Director of the Fraunhofer IZI (Picture: © Fraunhofer ICI)

This scrappy young city in the heart of Europe is rapidly becoming a magnet for successful start-ups and companies looking for plenty of room to grow, as well as a culture of cooperation and trust.

Spanish outgoing Agriculture Minister Luis Planas presenting the results of the Agriculture on Monday evening. © CE

At the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the adapted version of the EU Commission’s draft regulation on new genomic techniques.

Carthera SA

Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.
 

©UK.gov

On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.

In the Laboratory ©Valneva SE

Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.

© Giovanni Cancemi - stock.adobe.c

Researchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.

© 18percentgrey - stock.adobe.com

Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.